The Concussion You Never Recovered From.
Most men who have played contact sports, served in the military, or been in a significant accident have had at least one concussion. Many have had several. And a disturbing number never fully recovered.
Post-concussion syndrome (PCS) affects 15-30% of TBI patients beyond the expected recovery window. Symptoms include persistent brain fog, headaches, irritability, light sensitivity, sleep disruption, and difficulty concentrating. The standard medical approach is rest and symptom management. There is no FDA-approved treatment specifically for PCS.
The damage is neuroinflammatory: the initial impact triggers an inflammatory cascade that can persist for months or years. Microglial activation, blood-brain barrier disruption, and axonal injury create a chronic neuroinflammatory state that the brain cannot resolve on its own in some individuals.
Peptides that target neuroinflammation, neurotrophic factor support, and neural repair address the mechanisms that keep PCS patients stuck.
Cerebrolysin: The Neurotrophic Heavy Hitter.
Cerebrolysin is a porcine-derived neuropeptide complex that mimics endogenous neurotrophic factors (BDNF, NGF, GDNF, CNTF). It has over 200 published studies, including Phase III clinical trials for Alzheimer's disease and stroke recovery.
For TBI: Cerebrolysin research demonstrates reduced neuroinflammation, improved neuroplasticity, and enhanced cognitive recovery in traumatic brain injury models. A 2020 meta-analysis of Cerebrolysin in TBI showed statistically significant improvements in cognitive outcomes compared to standard care.
The mechanism is fundamentally different from symptom management. Cerebrolysin provides the raw neurochemical material (neurotrophic factors) that the brain needs to repair damaged neural connections. It does not mask symptoms—it supports structural recovery.
Protocol: 5-10 mL intramuscular, daily for 10-20 days. Post-acute TBI protocols in European clinics typically run 2-3 cycles with 4-6 week breaks between. Earlier intervention after injury correlates with better outcomes in the research.
Semax: BDNF on Demand.
Semax upregulates BDNF, the neurotrophic factor most directly responsible for neuroplasticity and neural repair. In Russian clinical practice, Semax is part of the standard stroke recovery protocol.
For concussion recovery, Semax provides several advantages: intranasal administration (no injection), rapid onset (15-30 minutes), and a well-characterized safety profile from 30+ years of clinical use. It supports the cognitive recovery that PCS patients need—improved attention, faster processing speed, and better memory consolidation.
Semax also modulates dopamine metabolism, addressing the motivational and mood disruptions that commonly accompany PCS. Many post-concussion patients describe a loss of drive and emotional flatness that conventional medicine attributes to "depression" but is actually dopaminergic dysfunction from neuroinflammation.
Dosing: 200-600 mcg per day intranasal, split into 2-3 administrations. Run 10-14 day cycles with equal time off. Can be layered with Cerebrolysin during intensive recovery cycles.
BPC-157: The Neuroprotective Wildcard.
BPC-157 is primarily known for musculoskeletal repair, but its neuroprotective research is substantial. Published studies demonstrate BPC-157's effects on dopaminergic system recovery, serotonin system modulation, and neuroprotection against various forms of brain injury.
The gut-brain axis connection is particularly relevant for TBI. Brain injury disrupts gut function through vagal and autonomic pathways, and gut dysfunction feeds back inflammatory signals to the brain. BPC-157 addresses both sides of this axis simultaneously.
For PCS patients with co-occurring GI symptoms (common after TBI), BPC-157 provides dual benefit: neuroprotection via systemic administration and gut repair via oral dosing.
Dosing: 250-500 mcg subcutaneous daily for systemic neuroprotection. Add oral BPC-157 250-500 mcg if GI symptoms are present.
The TBI Recovery Protocol.
Acute phase (0-4 weeks post-injury): BPC-157 500 mcg subcutaneous daily + Semax 400 mcg intranasal daily. Focus on neuroprotection and reducing secondary inflammatory damage.
Recovery phase (4-12 weeks): Add Cerebrolysin 5-10 mL IM daily for a 10-20 day cycle. This is the intensive neural repair window. Continue BPC-157 and Semax.
Maintenance phase (3-12 months): Semax 200-400 mcg intranasal in 10-14 day cycles. BPC-157 250 mcg daily or cycling 4 weeks on, 2 weeks off. Consider a second Cerebrolysin cycle at 6 months if cognitive recovery plateaus.
Chronic PCS (1+ years post-injury): The same protocol applies but expectations should be calibrated. Chronic neuroinflammation is harder to resolve than acute. Plan for 6-12 months of consistent protocol adherence with cognitive testing to track progress.
Critical: This is not a substitute for medical evaluation. Any suspected TBI should be assessed by a physician. Imaging (CT/MRI) may be necessary to rule out structural damage requiring intervention.
Blast Injury: The Military Angle.
Blast TBI from IEDs and explosions creates a unique injury pattern: diffuse axonal injury without the focal impact damage seen in sports concussions. The shockwave passes through the skull and disrupts neural connections across the entire brain.
Veterans with blast TBI represent the largest population of chronic PCS patients in the world. The VA estimates 430,000+ service members sustained TBI during the Iraq and Afghanistan conflicts alone.
The peptide protocol is the same as civilian TBI, but the injury profile means recovery may take longer and require more Cerebrolysin cycles. Veterans should also consider Selank for the anxiety and hypervigilance components that often accompany blast TBI.
The veteran community was the single largest source of public comments submitted to the PCAC docket for the July 2026 peptide review. This population has the most to gain from regulated peptide access.
◆ Key Takeaway
Cerebrolysin provides neurotrophic factor support for structural neural repair. Semax delivers BDNF upregulation and dopaminergic recovery. BPC-157 addresses neuroprotection and gut-brain axis dysfunction. Start BPC-157 + Semax immediately after injury. Add Cerebrolysin in the 4-12 week recovery window. Plan for 6-12 months of protocol adherence for chronic PCS.